Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas | recruiting | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01587352 | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT06081920 | A Study of IBI363 in Subjects With Advanced Melanoma | recruiting | Phase 2 | 180 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT07686835 | Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.(FIGURE-IM) | recruiting | Phase 2 | 70 | Radboud University Medical CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07230613 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma(NEOREM-NEO-1) | recruiting | Phase 2 | 50 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05704647 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06060613 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors(Agni-01) | recruiting | Phase 1 / Phase 2 | 208 | Obsidian Therapeutics, Inc.INDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | enrolling by invitation | Phase 2 | 48 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | active not recruiting | Phase 2 | 87 | Vyriad, Inc.INDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT02775851 | Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT06365619 | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma(NeoRelapse) | recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06961357 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 36 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT00539591 | Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma | active not recruiting | Phase 2 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | active not recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04722575 | Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma(NEO-TIM) | active not recruiting | Phase 2 | 95 | Fondazione Melanoma OnlusOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06932757 | Adjuvant Quisinostat in High-Risk Uveal Melanoma | recruiting | Phase 2 | 63 | University of MiamiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04305145 | Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | active not recruiting | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651618 | A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma(PERTIL-01) | not yet recruiting | Phase 2 | 10 | East Metropolitan Health Service, AustraliaOTHER_GOV | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | recruiting | Phase 1 / Phase 2 | 42 | Iovance Biotherapeutics, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06414590 | Neoadjuvant Tebentafusp for Uveal Melanoma | recruiting | Phase 2 | 19 | Thomas Jefferson UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644897 | Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05588453 | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | recruiting | Phase 1 / Phase 2 | 24 | Kari KendraOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05655312 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT04074096 | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis(BEPCOME-MB) | active not recruiting | Phase 2 | 10 | UNICANCEROTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07619898 | PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure(PHOENIX-ECP) | not yet recruiting | Phase 2 | 112 | Therakos LLCINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT03467516 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 34 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05912244 | A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07615881 | Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma(IpiD) | not yet recruiting | Phase 1 / Phase 2 | 18 | Amsterdam UMC, location VUmcOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT07422805 | Circulating Tumor DNA in Melanoma Patients(ctDNA) | active not recruiting | Phase 1 / Phase 2 | 176 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 30, 2026source: clinicaltrials